NCT06205329View on ClinicalTrials.gov

Study of WPV01 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

March 11, 2023

Study Completion Date

July 26, 2023

Conditions
Healthy Participants
Interventions
DRUG

WPV01 Dose 1-4

WPV01 Dose 1-4 or Placebo on day 1

DRUG

WPV01 Dose 5-8 and Ritonavir

WPV01 Dose 5-8 and Ritonavir or Placebo on day 1

DRUG

WPV01 Dose 9-12

WPV01 Dose 9-12 or Placebo from day 1 to day 6

DRUG

WPV01 Dose 13-15 and Ritonavir

WPV01 Dose 13-15 and Ritonavir or Placebo from day 1 to day 6

DRUG

WPV01 Dose 16

Cohort 1:WPV01 Dose 16 or Placebo (with high fat meal) Cohort 2:WPV01 Dose 16 or Placebo (fasted)

Trial Locations (1)

Unknown

Shulan(Hangzhou) Hospital, Hangzhou

All Listed Sponsors
lead

Westlake Pharmaceuticals (Hangzhou) Co., Ltd.

INDUSTRY